Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication.

AUTOR(ES)

Aukland, A

RESUMO

Fifty-one men with atherosclerotic intermittent claudication and haemorheological abnormalities completed a double-blind, one-year randomised trial of Ticlopidine (500 mg/day), a new antiplatelet agent. Ticlopidine caused significant inhibition of platelet aggregation but did not fully correct abnormalities of coagulation, viscosity, and fibrinolysis. There was no significant improvement in walking ability, Doppler ankle-pressure indices, or calf blood flow. Sustained platelet inhibition for 12 months was insufficient to correct the prothrombotic abnormality of extensive atherosclerosis.

Documentos Relacionados

• Self-administration of a questionnaire on chest pain and intermittent claudication.
• Reversible motor and sensory neurophysiological abnormalities in cauda equina claudication.
• Remote ischemic preconditioning in patients with intermittent claudication
• Exercise prescription using the heart of claudication pain onset in patients with intermittent claudication
• Neurogenic Intermittent Claudication